Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early-stage HER2-positive breast cancer

Bookmark and Share
Published: 1 Jun 2014
Views: 2484
Dr Edith Perez - Mayo Clinic, Rochester, USA

At a press conference at ASCO 2014, Dr Perez presents the findings from a large phase III study, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation), which suggest that post-surgery (adjuvant) treatment using a combination of two HER2-targeted drugs – trastuzumab and lapatinib – is no more effective than standard treatment with trastuzumab alone for women with early HER2-positive breast cancer.

Read the article for more.